Option chain shows key data for Conduit Pharmaceuticals's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Conduit Pharmaceuticals.

Conduit Pharmaceuticals (NASDAQ:CDT) Stock, Option Chain

Conduit Pharmaceuticals

Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Marijuana,Prescription.,Medical,Marijuana.,Close,Up,Cannabis,Buds.,Doctors,Prescription

News

Movers

Conduit shares are trading higher after the company announced it filed multiple patents related to VTAMA (tapinarof).

What&#39;s Going On With Conduit Pharmaceuticals Shares Friday?

Analyst strongly recommends investors to buy Zomato stock

Equities

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

BILL

DOCS

FARM

NKLA

Dow Dips 400 Points; US Adds Fewer Than Expected Jobs

Nasdaq index

AMZN

MGOL

Nasdaq Gains Over 50 Points; Amazon Issues Weak Outlook

Conduit Pharmaceuticals Inc. - Common Stock

Conduit Pharmaceuticals Inc

Infinitii Ai Inc

CDT Environmental Technology Investment Holdings Limited - ordinary shares

CDT Environmental Technology Investment Holdings Ltd

CDTI ADVANCED MATERIALS by CDTI Advanced Materials, Inc.

CDTi Advanced Materials Inc

Cidara Therapeutics Inc

Health Care

Press Releases

General

Conduit Pharmaceuticals Transitions to Phase II of Sarborg Collaboration to Support AI-Driven Drug Development

Financing

Conduit Pharmaceuticals Announces Debt Repayment and Partial Conversion of Senior Secured Note

Conduit Pharmaceuticals Partners with Charles River in Clinically Relevant Systemic Lupus Erythematosus Model

Conduit Progresses Phase II of its AI Initiative with Sarborg

Conduit Pharmaceuticals Provides Update on Nasdaq Stock Market Hearing Panel

Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658, and AZD5904

Legal

Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases

Conduit Pharmaceuticals Expands Partnership with Sarborg Limited to Leverage Machine Learning Data Analysis for Pipeline Optimization

Conduit Pharmaceuticals Announces up to $1,000,000 Share Repurchase Program

Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA® (tapinarof) with Enhanced Therapeutic and Market Extension Prospects

Comments

Conduit Pharmaceuticals

Conduit Pharmaceuticals (CDT) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga